Preventive and Treatment Interventions for Abdominal Ascites of Patients with Liver Cirrhosis: A Systematic Review of Randomized Controlled Trials

Overview

Journal Florence Nightingale J Nurs

Publisher Aves

Specialty Medical Education

Date 2021 Jul 15

PMID 34263244

Authors

Ferya Celik

Hicran Bektas

Affiliations

Soon will be listed here.

Abstract

Aim: This systematic review aimed to evaluate the efficacy of preventive and therapeutic approaches used in the management of ascites in liver cirrhosis.

Method: Literature review was done in "Scopus, Web of Science, CINAHL, ScienceDirect, PubMed MEDLINE, Ulakbim National Database, and Cochrane Library" databases using the keywords, "ascites, refractory ascites, liver cirrhosis, intervention, prophylaxis, treatment, nursing management, prevention, ascites management, randomized controlled trials," and 2,447 articles were obtained. The studies with low bias risk were included. This systematic review was planned by following the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement.

Results: A total of 11 randomized controlled trials were included. When the included studies were examined, ascites treatment approaches were evaluated in all of the studies; however, preventive approaches were not evaluated. It was found that mannitol, a diuretic drug, helps ascites management by contributing to weight loss, decrease in abdominal circumference, and urinary sodium excretion. The automatic low-flow ascites pump also reduced the need for large-volume paracentesis. There was a decrease in weight and abdominal circumference measurements when band compression was applied to the umbilicus.

Conclusion: Therapeutic approaches were found to be effective. It was thought that the lack of nursing practices and the prevention of ascites formation in the abdomen was an important deficiency. Randomized controlled trials were recommended for the prevention of abdominal ascites formation and the side effects of treatment on the patient.

References

Hanafy A, Hassaneen A . Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur J Gastroenterol Hepatol. 2016; 28(12):1455-1461. DOI: 10.1097/MEG.0000000000000743. View

Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A . Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2016; 152(1):157-163. DOI: 10.1053/j.gastro.2016.09.016. View

Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi F . Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018; 391(10138):2417-2429. DOI: 10.1016/S0140-6736(18)30840-7. View

Raza M, Qureshi U, Humayoun M, Waseem T, Akram J . Effect of intravenous mannitol in mobilization of resistant cirrhotic ascites. Eur J Gastroenterol Hepatol. 2010; 23(2):184-8. DOI: 10.1097/MEG.0b013e328342af25. View

Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H . Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2010; 46(1):78-85. DOI: 10.1007/s00535-010-0282-9. View

Stirnimann G, Banz V, Storni F, De Gottardi A . Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therap Adv Gastroenterol. 2017; 10(2):283-292. PMC: 5298482. DOI: 10.1177/1756283X16684688. View

Wong F, Gines P, Watson H, Horsmans Y, Angeli P, Gow P . Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010; 53(2):283-90. DOI: 10.1016/j.jhep.2010.02.036. View

Fullwood D, Purushothaman A . Managing ascites in patients with chronic liver disease. Nurs Stand. 2014; 28(23):51-8. DOI: 10.7748/ns2014.02.28.23.51.e8004. View

Volk M, Tocco R, Bazick J, Rakoski M, Lok A . Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol. 2011; 107(2):247-52. PMC: 3470789. DOI: 10.1038/ajg.2011.314. View

10.

Bernardi M, Caraceni P, Navickis R, Wilkes M . Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2011; 55(4):1172-81. DOI: 10.1002/hep.24786. View

11.

Thomson M, Volk M, Kim H, Piette J . An Automated Telephone Monitoring System to Identify Patients with Cirrhosis at Risk of Re-hospitalization. Dig Dis Sci. 2015; 60(12):3563-9. DOI: 10.1007/s10620-015-3744-3. View

12.

Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P . A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000; 342(23):1701-7. DOI: 10.1056/NEJM200006083422303. View

13.

Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M . Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol. 2017; 67(5):940-949. DOI: 10.1016/j.jhep.2017.06.010. View

14.

Volk M, Fisher N, Fontana R . Patient knowledge about disease self-management in cirrhosis. Am J Gastroenterol. 2013; 108(3):302-5. PMC: 3819196. DOI: 10.1038/ajg.2012.214. View

15.

Liang J, Zhang H, Zhao C, Wang D, Ma X, Zhao S . Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases. Int J Rheum Dis. 2017; 20(9):1219-1226. DOI: 10.1111/1756-185X.13015. View

16.

. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018; 69(2):406-460. DOI: 10.1016/j.jhep.2018.03.024. View

17.

Shah H, Abu-Amara M . Education provides significant benefits to patients with hepatitis B virus or hepatitis C virus infection: a systematic review. Clin Gastroenterol Hepatol. 2013; 11(8):922-33. DOI: 10.1016/j.cgh.2013.04.024. View

18.

Xing F, Tan Y, Yan G, Zhang J, Shi Z, Tan S . Effects of Chinese herbal cataplasm Xiaozhang Tie on cirrhotic ascites. J Ethnopharmacol. 2011; 139(2):343-9. DOI: 10.1016/j.jep.2011.10.040. View

19.

Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath P, Del Arbol L . Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002; 123(6):1839-47. DOI: 10.1053/gast.2002.37073. View

20.

Hampel H, Bynum G, ZAMORA E, El-Serag H . Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol. 2001; 96(7):2206-10. DOI: 10.1111/j.1572-0241.2001.03958.x. View